The "anticancer drug" of subverting tradition, accurately locking cancer cells, and advanced cancer are also rescued

German philosopher Leibnitz said: "There are no two exactly the same leaves in the world."

The same is true in the field of lung cancer. Even lung cancer of the same type will be different.

Anti -cancer is a fine work. We must eliminate cancer cells, but we cannot affect normal cell work. Under this idea, precise treatment came into being. In just two decades, lung cancer treatment has obtained a leap breakthrough:

The overall mortality rate of lung cancer declines: The mortality rate of lung cancer in Chinese men decreased by 0.6%, and the mortality rate of lung cancer in women also showed a downward trend [1]! Professor Wu Yilong, Lifetime Director of the People's Hospital of Guangdong Province, said: Professor Wu Yilong said: The 5-year survival rate of patients with advanced lung cancer in my country can reach 15-20%, while only 0-1%[2] more than ten years ago.

This huge improvement is inseparable from the development of targeted drugs!

01

The first targeted drug knocks on the new door of lung cancer treatment

Do you know what is the first targeted medicine that Chinese lung cancer patients take?

The answer is Gefitinib!

At an international cancer conference in 2000, the new lung cancer drug Gitfitinib appeared;

In 2004, the imported Gitfitinib was approved in my country for second or more treatment for advanced non -small cell lung cancer;

In 2010, based on the results of iPass research, Gefeitinib was approved in my country for the treatment of advanced non -small cell lung cancer in China [3];

In 2019, based on Flaura research results, Oshitinib was approved in my country for the treatment of EGFR mutations positive non -small cell lung cancer first -line treatment [4].

Nowadays, lung cancer targeting drugs are sprayed. There are 8 targeted drugs for EGFR mutations. As of July 2021, 707 new drugs are developing for lung cancer.

Since patients with lung cancer have so many "life -saving medicines", how can we use them more accurately? Fun friends often have the following problems:

① So many targeted medicines, which medicines are suitable for me? ② What should I do if I eat targeting medicine? ③ After Oshitininib resistance, can the previous "first and second -generation old medicine" be used for new use? ④ Can a targeting medicine be reduced after surgery?

02

Experts live, ignite the light of life of lung cancer patients

In order to help more patients answering doubts, the targeted therapy is "good" with "good". Under the guidance of the Chinese Anti -Cancer Association Popular Science Professional Committee, the sixth theme of the "Pulmonary Power" in 2022 was "Pinjo Chase pursuit of pursuit of victory pursuit" in 2022. ! Popular science live broadcast of postoperative assistance, dysplasia of drug resistance, and targeted therapy for the whole process ".

In this live broadcast, we are very honored to invite three lung cancer experts:

Professor Jiang Guanming from the Second Department of Internal Medicine of Dongguan Hospital Affiliated to Southern Medical University;

Professor Xiong Hailin from the Department of Internal Medicine of the People's Hospital of Huizhou City;

Professor Peng Bin from Shenzhen People's Hospital.

Live theme

In this live broadcast, Professor Jiang Guanming will discuss the precise treatment of advanced lung cancer for friends; Professor Xiong Hailin will do what to do after the science popularization TKI drug resistance. Essence

Live information

Live broadcast time

17: 00-19: 00 on September 8

Live appointment

Method 1: The public account of the Chinese Anti -Cancer Association Popular Science Platform "Tumor" public welfare popular science popularization channel, make an appointment to watch.

Expert Introduction

Professor Jiang Guanming

Deputy Chief Physician of the Second District of the Internal Medicine of Dongguan Hospital Affiliated to Southern Medical University

Member of the lymphoma Professional Committee of the Guangdong Anti -Cancer Association

Harvard Medical College for short -term studies, visiting scholars at the Italian National Cancer Center

"Healthy China 2030" Consultant Consultant Consultant Consultation Project Team of Cancer Cancer

Member of the Professional Committee of Cancer Metabolism and Treatment of the Chinese Medical Doctors Association

IASLC (International Society of International Lung Cancer) Member

The third director of the Guangdong Clinical Pilot Association

Second Director of Southern Tumor Clinical Research Association (CSWOG)

Deputy Chairman of the Cancer Society of Cancer Cancer in Guangdong Province

Deputy Chairman of the Chemical Management Association of Health Management Association of Health Management Association

Member of the Department of Internal Medicine of the Cancer Association of Guangdong Medical Association

Professor Xiong Hailin

Chief physician of the Department of Internal Medicine of the People's Hospital of Huizhou Central People's Hospital

3rd Nanyue Good Doctor

Training

Southern Medical University In -service Ph.D.

Good at chemotherapy, biological therapy, molecular targeted therapy and other internal medicine treatment of various malignant tumors, especially diagnosis and treatment of lung cancer, malignant lymphoma, nasopharyngeal cancer, digestive tract tumors, primary liver cancer, melanoma, etc.

Professor Peng Bin

The attending physician of thoracic surgery at Shenzhen People's Hospital

He is engaged in clinical, scientific research and teaching work all year round. Good at the standardization and multi -disciplinary comprehensive diagnosis and treatment of lung cancer, esophageal cancer, neutral tumor and other chest tumors. Familiar with thoracoscopic minimally invasive surgery for lung cancer, esophageal cancer, neutral tumor, funnel chest, polyphonic sweat, pneumothorax, pneumoid dysplasia, and bronchial dilatation. Proficient in participating in single -hole thoracoscopic surgery, non -intubation autonomous breathing anesthesia surgery, robotic auxiliary chest disease surgery and other thoracic minimally invasive techniques

end

Cancer cells are actually very cunning. We are seeking better anti -cancer methods. Cancer cells are also thinking about how to escape "killing". In this "long -lasting war", doctors, patients, and family members must be together. Only constantly constantly constantly In order to learn and explore, the road of "healing" can be brighter and brighter!

Source

[1] Zheng RS, ZHANG SW, ZENG HM, Wang SM, Sun KX, Chen R, Li L, Wei WQ, He J. Cancer Incision and Mortality in China, 2016 [j]. JNCC, 2022, 2 (1): 1-9. Doi: https://doi.org/10.1016/j.jncc.2022.02.002.9.

[3] MOK TS, Wu YL, Thongprasert S, et al. Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma [J]. N Engl J Med. 2009; 361 (10): 947-57.

[4] Ramalingam SS, VANSTEENKISTE J, Planchard D, et al. Overall Survival with Osimertinib in Untreated, EGFR-MUTATED Advanced NSCLC [J].

- END -